Bridgewater, NJ – December 4, 2025 – Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company dedicated to developing transformative therapies for patients with serious diseases, has made headlines with its recent announcement regarding the granting of inducement awards to 92 new employees. This strategic move aligns with the company's mission to cultivate a strong workforce that can drive innovation and excellence in the biopharmaceutical sector.

1. Inducement Awards under Nasdaq Rule

The inducement awards, totaling 44,273 restricted stock units and options for 2,490 shares of common stock, were granted as a material inducement for the new employees’ entry into their respective roles at Insmed. These awards come under the Insmed Incorporated 2025 Inducement Plan, specifically designed to comply with Nasdaq Listing Rule 5635(c)(4).

The grants were officially approved by Insmed's Compensation Committee and were awarded to employees who commenced their employment on November 28, 2025. The exercise price for the stock options has been set at $207.77 per share, reflecting the closing trading price on the Nasdaq Global Select Market on the date of the grant.

2. Vesting Schedules for Awards

The granted awards come with specific vesting schedules designed to encourage employee retention and performance:

Restricted Stock Units (RSUs): These units have a four-year vesting period, where 25% of the shares will vest on each anniversary of the month following the grant date, contingent upon the employee's continued service with Insmed.

Stock Options: The options also feature a four-year vesting schedule but with a longer term of 10 years. Here, 25% of the shares will vest on the first anniversary of the grant date, with an additional 12.5% vesting every six months thereafter until the fourth anniversary.

This structured approach to employee compensation reflects Insmed's commitment to fostering a motivated workforce that is aligned with the company’s long-term goals and vision.

3. Insmed's Commitment to Innovation and Patient Care

Insmed is recognized not only for its innovative drug development but also for its dedication to patient care. The company is advancing a diverse portfolio of therapies, particularly in pulmonary and inflammatory conditions, which includes two approved treatments for chronic lung diseases. Additionally, Insmed is actively engaged in early-stage programs that explore a variety of cutting-edge technologies, including gene therapy and AI-driven protein engineering.

Headquartered in Bridgewater, New Jersey, Insmed prides itself on being a top employer in the biopharmaceutical industry, having earned accolades such as being ranked as the No. 1 *Science* Top Employer for five consecutive years. The company maintains research and operational facilities across the United States, Europe, and Japan, further solidifying its global presence and influence within the biopharmaceutical sector.

4. Conclusion

Insmed's latest inducement grants not only highlight its strategic hiring practices but also reinforce its commitment to building a robust and dedicated workforce. As the company continues to innovate and expand its portfolio of therapies, it remains focused on transforming the lives of patients facing serious diseases. With a clear vision for the future and a commitment to excellence, Insmed is poised to make significant contributions to the biopharmaceutical landscape in the years to come.

Original press release